Clinical trials sponsored by Shanghai Pulmonary Hospital, Shanghai, China

Phase breakdown

Conditions studied

Recruiting trials led by Shanghai Pulmonary Hospital, Shanghai, China

• A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
  NCT06780826 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma
  NCT06528847 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 1 location
• An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting
  NCT06749886 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
  NCT05838053 · Phase: Not specified · Ages: 20 Years to 79 Years · Sex: All (male and female) · 1 location
• Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
  NCT06749860 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
  NCT05053802 · Phase: Phase 2 · Ages: 18 Years to 79 Years · Sex: All (male and female) · 6 locations
• Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
  NCT05965024 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment
  NCT05857800 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
  NCT07408635 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
  NCT05766800 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
  NCT05503667 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
  NCT04728724 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
  NCT06987734 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
  NCT06256237 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
  NCT06758700 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
  NCT04937283 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years to 79 Years · Sex: All (male and female) · 14 locations
• Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
  NCT03351842 · Phase: Phase 2 · Ages: 19 Years to 70 Years · Sex: All (male and female) · 1 location
• Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine
  NCT07134660 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• WSI Based DL for Diagnosing the IASLC Grading System of Lung Adenocarcinoma
  NCT05925764 · Phase: Not specified · Ages: 18 Years to 85 Years · Sex: All (male and female) · 3 locations

Common questions

How many trials is Shanghai Pulmonary Hospital, Shanghai, China recruiting for?

Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor of 19 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.